A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY)
Mental Health & Behavioral Research
What is the purpose of this trial?
The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB).
The secondary objectives of this study are to evaluate the safety and tolerability of BIIB104 in participants with CIAS, and to evaluate the efficacy of BIIB104 in participants with CIAS on measures of cognition, functioning, and psychiatric symptomology.
- Ages18 years - 50 years
- Trial withBiogen MA, Inc.
- Start Date03/20/2020
- End Date04/06/2020
- Last Updated11/17/2021
- Study HIC#2000026887